Basic Information
| LncRNA/CircRNA Name | LINC00221 |
| Synonyms | NA |
| Region | GRCh38_14:106482439-106521073 |
| Ensemble | ENSG00000270816 |
| Refseq | NR_027457 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qRT-PCR, Western blotting etc. |
| Sample | 40 NSCLC (including 24 cisplatin-resistant NSCLC tissues and 16 cisplatin-sensitive NSCLC tissues) and 10 adjacent normal tissues samples, The normal bronchial epithelial cell line HBE and five lung adenocarcinoma cell lines (H1299, A549, H1299/CR, A549/CR and SK-MES-1) |
| Expression Pattern | up-regulated |
| Function Description | Linc00221 was highly expressed in cisplatin-resistant NSCLC tissues and cells and closely associated with poor prognosis. Linc00221 promoted the cisplatin resistance of NSCLC and miR-519a was a direct target of Linc00221. In addition, miR-519a could promote cisplatin sensitivity in NSCLC cells by targeting ZBTB5. Linc00221 could mediate the cisplatin sensitivity in NSCLC by adsorbing miR-519a to prevent its down-regulation of ZBTB5. |
| Pubmed ID | 31029744 |
| Year | 2019 |
| Title | Linc00221 Modulates Cisplatin Resistance in Non-Small-Cell Lung Cancer via Sponging miR-519a |
External Links
| Links for LINC00221 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |